Prosecution Insights
Last updated: July 17, 2026
Application No. 18/290,888

PHARMACEUTICAL OR FODD SUPPLEMENT FORMULATION CONTAINING ALPHA-LACTALBUMIN AND BUTYRIC ACID OR A SALT THEREOF

Non-Final OA §103
Filed
Jan 22, 2024
Priority
Jul 23, 2021 — IT 102021000019613 +1 more
Examiner
TRUONG, QUANGLONG N
Art Unit
Tech Center
Assignee
Kolfarma S R L
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
505 granted / 642 resolved
+18.7% vs TC avg
Strong +24% interview lift
Without
With
+23.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
51 currently pending
Career history
681
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
74.4%
+34.4% vs TC avg
§102
2.1%
-37.9% vs TC avg
§112
5.4%
-34.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 642 resolved cases

Office Action

§103
DETAILED ACTION Status of Application The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections – 35 U.S.C. 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-18 are rejected under 35 U.S.C. 103 as being unpatentable over Wang (CN106036140A Machine Translation). Regarding claims 1-18, Wang is drawn to a piglet starter feed. The functional feed includes one or more of the following: feed powder, maltodextrin, whey powder, whey protein concentrate, glucose (sweetener), plant essential oils, sodium butyrate. The nutritional characteristics and palatability of creep feed are also fully expressed. The creep feed of this invention is nutritionally complete and balanced, palatable, and piglets like to eat it, resulting in high feed intake and low disease incidence (abstract). Wang discloses a piglet starter feed, the components of which are calculated by weight as follows: 100 parts feed powder, 46 parts maltodextrin, 80 parts whey powder (comprises alpha-lactalbumin), 30 parts whey protein concentrate (comprises alpha-lactalbumin), 0.2 parts plant essential oil (flavoring), 4 parts sodium butyrate (Example 1; [0030]). Wang discloses crushed granules (powder) [0021]. Wang does not explicitly disclose the formulation as claimed together in one single embodiment. However, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the teachings of Wang to arrive at the instant invention, with the motivation that Wang discloses each of the required components and amounts, and for the same purpose of a functional feed (abstract). Further, one having ordinary still in the art would reasonably expect success in combining prior art elements according to known methods to yield predictable results, see MPEP 2141. The Supreme Court has acknowledged: When a work is available in one field of endeavor, design incentives and other market forces can prompt variations of it, either in the same field or a different one. If a person of ordinary skill can implement a predictable variation... 103 likely bars its patentability...if a technique has been used to improve one device, and a person of ordinary skill in the art would recognize that it would improve similar devices in the same way, using the technique is obvious unless its actual application is beyond that person’s skill. A court must ask whether the improvement is more than the predictable use of prior-art elements according to their established functions......the combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results (see KSR International Co. v. Teleflex Inc., 82 USPQ2d 1385 U.S. 2007) (emphasis added). From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. Pertinent Art Not Relied Upon Examiner has identified Kuang et al. (US 20180161292 A1) drawn to nutritional compositions containing dietary butyrate (abstract), the dietary butyric acid may also be provided in a coated form. For example, coating certain glycerol esters of butyric acids with fat derived materials, such as mono- and di-glycerides; sugar and acid esters of glycerides; phospholipids; plant, animal and microbial derived proteins and hydrocolloids, such as starches, maltodextrins [0067], alpha lactalbumin [0212], powdered nutritional formulation [0236], but has not directly relied upon the teachings from the reference in this action. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to QUANGLONG N TRUONG whose telephone number is (571)270-0719. The examiner can normally be reached on 8:00 am-5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /QUANGLONG N TRUONG/Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Jan 22, 2024
Application Filed
Jun 03, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678387
COMPOSITION FOR ALLEVIATING HAIR LOSS OR PROMOTING HAIR GROWTH
3y 11m to grant Granted Jul 14, 2026
Patent 12678411
Nanoformulations of Pazopanib, Compositions Comprising the Same and Methods of Treating Osteoarthritis
2y 7m to grant Granted Jul 14, 2026
Patent 12673017
ULTRA-MILD, CONCENTRATED AND SELF-PRESERVING CLEANSING COMPOSITIONS FOR PERSONAL CARE
2y 10m to grant Granted Jul 07, 2026
Patent 12673023
MEDICINE CONTAINER COMPRISING LIQUID PHARMACEUTICAL COMPOSITION OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE
2y 7m to grant Granted Jul 07, 2026
Patent 12642275
ANTIMICROBIAL LIQUID COMPOSITION AND USE THEREOF AS A PRESERVATIVE ACTIVATOR IN COSMETIC PRODUCTS
2y 12m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
99%
With Interview (+23.7%)
2y 2m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 642 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month